Stay updated with breaking news from Pharm Olam. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Etrasimod was effective and well tolerated as an induction and maintenance therapy in patients with moderately to severely active ulcerative colitis. Etrasimod is a treatment option with a unique combination of attributes that might address the persistent unmet needs of patients with ulcerative colitis.
Cathal Friel to continue in executive chairman role under new management structure
Share this article Share this article HOUSTON, Jan. 19, 2021 /PRNewswire/ -- Pharm-Olam, a global mid-sized clinical research organization (CRO), has been selected by the U.S. Department of Defense's (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to lead and provide full service clinical trial support of the Adalimumab COVID Therapeutic Trial. The JPEO-CBRND awarded Pharm-Olam a $36.3 million agreement to execute an adaptive, outpatient Phase II/III clinical trial of the monoclonal antibody, where adalimumab will be tested as a tre...